Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05364021 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
A Phase 1 study of Dravet Syndrome and Lennox Gastaut Syndrome, sponsored by Longboard Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT05364021: Completed Phase 1 study of Dravet Syndrome and Lennox Gastaut Syndrome, sponsored by Longboard Pharmaceuticals.
NCT05364021 is a Phase 1 study of Dravet Syndrome and Lennox Gastaut Syndrome that has completed, run by Longboard Pharmaceuticals. The registered enrollment target is 52 participants, below the 106-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05364021, a Phase 1 study of Dravet Syndrome and Lennox Gastaut Syndrome, has completed, sponsored by Longboard Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
Primary Outcome
Incidence and severity of adverse events, including serious adverse events and adverse events leading to study discontinuation and clinically significant changes in vital signs, physical examination endpoints, clinical safety laboratory values and ECGs
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LP352
Study Locations (20)
Florida
- Northwest Florida Clinical Research Group - Gulf Breeze
- University of Miami - Miami
- Advent Health Orlando - Orlando
- Research Institute of Orlando - Orlando
- University of South Florida - Tampa
California
- Rancho Los Amigos National Rehabilitation Center (RLANRC) - Downey
- Children's Hospital of Orange County - Orange
- University of California San Francisco - San Francisco
New York
- Boston Children's Health Physicians LLP - Hawthorne
- New York University Langone Hospital - Long Island - Mineola
- Northwell Health - New York
Arizona
- University of Arizona - Health Sciences Center - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Idaho
- Consultants in Epilepsy and Neurology - Boise
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 1 |
What the finished NCT05364021 record still lists
NCT05364021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 106-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (51% lower).
The record links to 3 conditions, with Dravet Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05364021 names 20 study sites across 12 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT05364021 about?
NCT05364021 is a clinical study titled "Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies". The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
What is the current status of trial NCT05364021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2022-03-03. Estimated completion is 2023-11-20.
What conditions does trial NCT05364021 study?
This clinical trial studies the following conditions: Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathy.
What interventions are being tested in trial NCT05364021?
The interventions under investigation include: Placebo (DRUG), LP352 (DRUG).
Who is sponsoring clinical trial NCT05364021?
This trial is sponsored by Longboard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05364021 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05364021's enrollment target sits among peer trials
52 7th of 12 higher than 6 of 12 other Dravet Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dravet Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
COMPLETED · Phase 1
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RECRUITING · Phase 3
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
-
GABA Biomarkers in Dravet Syndrome
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI